Johnson & Johnson: Carcinoma trials

The registry lists 10 Carcinoma studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 1Phase 2 4Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Phase 2Results posted
• NeuWave Microwave Ablation HCC China StudyCompletedNCT03783871Not applicableResults posted
• NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the LungTerminatedNCT03603652Not applicableResults posted
• Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in KoreaCompletedNCT03586050Not applicableResults posted
• A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based ChemotherapyTerminatedNCT01840943Phase 3Results posted
• NEUWAVE Flexible Probe Study #2WithdrawnNCT03713099Not applicable
• CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based ChemotherapyTerminatedNCT00653952Phase 3
• A Study of CNTO 328 in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00265135Phase 1/2
• Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based ChemotherapyCompletedNCT00216645Phase 2
• Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial CarcinomaCompletedNCT00050440Phase 2